E Ink Partners with MIT Solve to Launch Innovation Prize for Global Challenges
BILLERICA, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- E Ink (8069.TW), the originator, pioneer, and global commercial leader in ePaper technology, announced today its collaboration with MIT Solve, an initiative of the Massachusetts Institute for Technology with a mission to drive innovation to solve world challenges. The E Ink Innovation Prize will award up to $300,000 over the next three years to teams helping solve the world's most pressing issues.
'This partnership with MIT Solve underscores our commitment to leveraging ePaper technology to address some of the world's most pressing challenges,' said Johnson Lee, CEO, E Ink. 'We believe that by supporting innovation, we can make a significant impact on global issues and drive sustainable change.'
The inaugural E Ink Solve Global Challenge opened for applications on February 3, 2025, with prize recipients selected in August, and official project kick off in September. The E Ink Innovation Prize is open to solutions that utilize ePaper materials, technology, or displays to address problems of global importance in any of Solve's areas of impact, including topics such as architecture, education, or intercultural understanding.
'Working with E Ink, a company that originally spun out of the MIT Media Lab in 1997, is a full circle moment,' said Hala Hanna, Executive Director of MIT Solve. 'This level of support is what drives scale and transformational impact. We look forward to working alongside E Ink to advance pivotal tech-based solutions that create a better future for all.'
MIT Solve finds and supports tech-based solutions to global challenges through open innovation challenges and partnerships, and in part with its collaboration with E Ink, aims to achieve a more sustainable and equitable future for all. The Innovation prize will be awarded to up to four Solver teams, with additional support from E Ink through project implementation. To learn more or to apply, please visit https://solve.mit.edu/challenges.
E Ink continues to receive recognition across its climate strategy, privacy protection, and business ethics, with its ongoing inclusion in the Dow Jones Sustainability World Index (DJSI World) and the Dow Jones Sustainability Emerging Markets Index (DJSI Emerging Markets). The company has revised its 2025 renewable energy goal to RE65, aiming for RE100 across all operations. Additionally, E Ink's displays have been recognized for their environmental contributions, with 99.9% of product sales revenue qualifying as green revenue and is noted for its energy efficiency and eye health benefits, being the first display technology to receive certification from the International Dark-Sky Association.
About E Ink
E Ink Holdings Inc. (8069.TWO), based on technology from MIT's Media Lab, provides an ideal display medium for applications spanning eReaders and eNotes, retail, home, hospital, transportation, logistics, and more, enabling customers to put displays in locations previously impossible. E Ink's electrophoretic display products make it the worldwide leader for ePaper. Its low power displays enable customers to reach their sustainability goals, and E Ink has pledged using 100% renewable energy in 2030 and reaching net zero carbon emissions by 2040. E Ink has been recognized for their efforts by receiving, validation from Science-Based Targets (SBTi) and is listed in both the DJSI World and DJSI Emerging Indexes. Listed in Taiwan's Taipei Exchange (TPEx) and the Luxembourg market, E Ink Holdings is now the world's largest supplier of ePaper displays. For more information please visit www.eink.com. E Ink. We Make Surfaces Smart and Green.
Contact
V2 Communications on behalf of E Ink
About MIT Solve:
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to drive innovation to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation challenges, Solve finds incredible tech-based social innovators from all around the world. Solve then brings together MIT's ecosystem and a community of supporters to fund and scale these innovators to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu.
Contact
Bridget Weiler
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Black Hills Corp. Receives Approval For 99 MW Dispatchable Generation Resource in South Dakota
RAPID CITY, S.D., June 11, 2025 (GLOBE NEWSWIRE) -- Black Hills Corp. (NYSE: BKH) today announced that its South Dakota electric utility subsidiary serving South Dakota and eastern Wyoming has received approval from the Wyoming Public Service Commission for a certificate of public convenience and necessity (CPCN) that supports the need for its Lange II Project, a 99 MW dispatchable generation resource in Rapid City, South Dakota. The approval allows commencement of construction of the project, which addresses a capacity deficit resulting from the retirement of other aging generation units, as well as an increase in planning reserve margin to ensure the utility has a reliable energy supply. Lange II will include six reciprocating internal combustion engines (RICE) with dual-fuel optionality of natural gas and diesel, and related interconnection facilities. These were identified as the least-cost resource to continue to reliably serve customers in South Dakota and eastern Wyoming. The project is estimated to cost $280 million. 'We are committed to providing our customers with the safe, reliable and cost-effective electric service they depend on,' said Linn Evans, president and CEO of Black Hills Corp. 'Notably, these RICE units will enhance resiliency of the electric system and the ability to quickly respond to fluctuations in demand needs for our customers.' Construction is planned to commence during the third quarter of 2025 and the project is expected to start serving customers in the second half of 2026. Black Hills CorporationBlack Hills Corp. (NYSE: BKH) is a customer-focused, growth-oriented utility company with a tradition of improving life with energy and a vision to be the energy partner of choice. Based in Rapid City, South Dakota, the company serves 1.35 million natural gas and electric utility customers in eight states: Arkansas, Colorado, Iowa, Kansas, Montana, Nebraska, South Dakota and Wyoming. More information is available at Investor RelationsSal Diaz605-399-5079Investorrelations@ 24-Hour Media Relations Line888-242-3969Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
23 minutes ago
- Associated Press
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit . About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking information or statements'. Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate' 'anticipate' or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the 'Risk Factors' section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi Medical Stefano Picone Chief Financial Officer [email protected] (416) 483-0100 Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]
Yahoo
29 minutes ago
- Yahoo
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ETLINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi MedicalConavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit About Virtual Investor Conferences®Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking StatementsThis press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are "forward-looking information or statements". Often but not always, forward-looking information or statements can be identified by the use of words such as "shall", "intends", "anticipate", "believe", "plan", "expect", "intend", "estimate" "anticipate" or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "might", "can", "could", "would" or "will" be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the "Risk Factors" section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or regulatory authority has approved or disapproved the content of this press the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi MedicalStefano PiconeChief Financial Officerir@ 483-0100 Virtual Investor Conferences John M. ViglottiSVP Corporate Services, Investor AccessOTC Markets Group (212) 220-2221johnv@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
